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Supplementary Figure 1. NMR spectroscopy of the Hsp90/Aha1-interaction.  
A) Localization of 13C-labeled isoleucine methyl groups (yellow spheres) on the 
extended conformation of the human Hsp90 dimer (1) (modified from PDB id 5fwk) (2).  
B) Sequence-specific analysis of the changes in Hsp90 peak intensity upon addition of 
Aha1. Blue and red bars represent 1:2 and 1:4 molar ratios, respectively. The orange 
and red lines mark I/I0 thresholds of 0.7 and 0.5, respectively, to color code residues in 
Figure 1C-E: I/I0<0.5 in red; I/I0= 0.5-0.7 in orange; I/I0= 0.7-1 in yellow. Error bars (in 
grey, very small) were calculated using the spectral signal-to-noise ratios.  
C) Chemical shift perturbation plot of the Hsp90/Aha1-interaction. Hsp90 domains are 









Supplementary Figure 2. Multiple regions of the N-terminal domain of Hsp90 are 
affected by Aha1 binding.  
Isoleucine residues of the N-terminal domains of Hsp90, which are perturbed by 
addition of Aha1 to full-length Hsp90 (Figure 1B), are represented by spheres using the 
structure of the closed Hsp90 dimer (PDB id 5fwk). The color code is the same as used 






















Supplementary Figure 3. Conformational changes in the N-terminal domain of 
Hsp90 upon nucleotide binding and dimerization.  
A) Superposition of the structure of the N-terminal domain of Hsp90 (Hsp90N) in the 
absence of ADP (PDB id: 5j2v) with two structures in the presence of ADP (PDB id: 
1am1, ADP-bound yeast Hsp90; 1uym, Hsp90Nb bound to the PU3 analog of ATP). 
ADP is displayed with green sticks. Nucleotide binding to Hsp90N induces changes in 
the proximal part of helix 4 (highlighted in magenta, yellow circle). Isoleucine residues, 
for which the methyl cross-peaks are perturbed by binding of ADP to full-length Hsp90 
(please see Figure 3H), are displayed with blue spheres.  
B) Superposition of monomeric Hsp90N structure (PDB id: 1uym) with Hsp90N in the 
Hsp90 dimer (PDB id: 5fwk), revealing large conformational changes (indicated by 
arrows) during nucleotide binding, dimer closure and Hsp90N dimerization: β-Strand 1 
swaps between domains and helix 4 folds around the hinge (yellow circle) to fully close 
the nucleotide binding pocket. Regions undergoing strong conformational changes are 
marked in magenta and dark blue in monomeric and dimeric Hsp90N, respectively. 
Isoleucine residues, for which the methyl cross-peaks are perturbed upon addition of 
Aha1 to full-length Hsp90 in the absence of nucleotide (Figures 1, S1) are displayed by 
spheres (red and light blue). I20, I27, I28, I37, I98, I122 and I125 probe conformational 
rearrangements in Hsp90N upon dimerization, while I361 and I389 are located on the 
Hsp90M loop that clamps the new conformation of Hsp90N’s helix 4. All these 
isoleucine residues are affected upon Aha1 binding in the absence of nucleotide, 
suggesting that the co-chaperone induces conformational rearrangements in Hsp90N 
similar to those induced by nucleotide binding and dimerization. Light blue spheres 
mark the Aha1 cis binding interface of Hsp90N (Figure 2B). ATP is displayed with 




Supplementary Figure 4. Aha1 binds weakly to monomeric Hsp90NM.  
A-B) Methyl-TROSY spectra of Hsp90NM showing that Aha1-binding does not 
promote the appearance of new isoleucine cross-peaks (A), in contrast to Aha1-binding 
to full-length, dimeric Hsp90 (B, same as in Figure 1B). Molar ratios are indicated. For 
clarity, cross-peaks were labeled relative to Hsp90 domains.  
C) Sequence-specific decrease in the intensities of methyl cross-peaks of Hsp90NM 
upon addition of equimolar (blue) and 4-fold molar excess (red) of Aha1. An orange 
dashed line at I/I0=0.7 marks the threshold below which Hsp90NM residues are 
considered to be significantly affected upon addition of Aha1. Error bars (grey bars, 
very small) are based on spectral S/N ratios.  
D) Selected region of the Hsp90NM methyl-TROSY spectra in the absence (red) and 
presence (green) of Aha1 (as shown in panel (A)). I72 and I407 were strongly shifted.  
E) SAXS P(r) distribution of the mixture (in green) indicates that the complex is not 
stable and that it is highly dynamic and/or polymorphic. A theoretical curve for the 





Supplementary Figure 5. E67K mutation in the N-terminal domain of Aha1 
diminishes binding to human Hsp90.  
A) Superposition of isoleucine methyl-TROSY spectra of Hsp90 in the absence (red) 
and presence of a 2-fold (blue) and 4-fold molar excess of the E67K-mutant Aha1. For 
clarity, cross-peaks were labeled relative to Hsp90 domains.  
B-D) Sequence-specific changes in the intensity (B) and position (C) of isoleucine 
methyl cross-peaks of Hsp90 upon addition of the E67K-mutant Aha1 (as displayed in 
panel (A)). Error bars (in grey, very small) were calculated based on spectral S/N 
ratios. Isoleucine residues with intensity ratios (I/I0) below 0.8 are displayed as spheres 
in (D), with the N-terminal domain of Aha1 (Aha1-N) positioned according to PDB id 
1usu (4). The Hsp90 dimer is shown in an extended, ATP-incompetent conformation 
(modified from PDB id 5fwk (2)) following the known inability of the E67K-mutant Aha1 
to stimulate Hsp90’s ATPase activity (5).  
E) The side-chain of E67 (in red sticks) in Aha1-N is surrounded by a cluster of 
positively charged residues of Hsp90M (K398, K400, R404 and K405, represented in 




Supplementary Table 1. Hsp90 Ile δ1 CH3 assignments. Four unassigned residues in 
Hsp90C domain are marked with C. 
 
Domain Residue 13C (ppm) 1H (ppm) 
Hsp90N 
I20 8.802 0.826 
I27 10.587 0.554 
I28 8.001 0.706 
I37 12.343 0.603 
I43 10.878 0.663 
I53 11.607 0.828 
I72 11.779 0.723 
I74 11.752 0.59 
I75 12.756 0.56 
I90 12.773 0.801 
I98 12.214 0.524 
I104 9.069 0.746 
I122 10.678 0.559 
I125 11.686 0.573 
I145 11.882 0.69 
I174 10.327 0.519 
I181 11.82 0.806 
I208 6.019 0.816 
I212 10.647 0.769 
CL 
I224 10.478 0.753 
I249 9.799 0.781 
I271 10.048 0.804 
I276 10.032 0.759 
Hsp90M 
I287 9.717 0.355 
I295 11.679 0.677 
I334 8.549 0.516 
I352 11.474 0.466 
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I361 6.915 0.606 
I369 9.086 0.376 
I376 11.907 0.867 
I389 11.693 0.765 
I399 10.229 0.771 
I403 11.347 0.753 
I407 11.553 0.666 
I440 10.737 0.705 
I482 11.923 0.666 
I485 11.962 0.84 
I516 11.483 0.752 
Hsp90C 
I579 11.053 0.583 
I590 12.247 0.862 
I604 10.403 0.675 
I627 8.603 0.62 
I679 11.014 0.946 
I683 8.448 0.616 
C 10.282 0.688 
C 9.709 0.499 
C 11.713 0.731 
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